Status:
TERMINATED
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
Lead Sponsor:
Frank C Sciurba
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
COVID-19
Eligibility:
All Genders
40-80 years
Phase:
PHASE3
Brief Summary
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagno...
Detailed Description
The COVID-19 Outpatient Thrombosis Prevention Trial is a multi-center adaptive randomized double-blind placebo-controlled platform trial to compare the effectiveness of anti-coagulation with anti-plat...
Eligibility Criteria
Inclusion
- Inclusion:
- COVID-19+ in past 14 days
- Platelets \> 100,000
- eGFR \> 30ml/min
- Exclusion:
- Hospitalized
- Contradiction/ other indication for anti-coagulation
- Pregnancy
- Active cancer
Exclusion
Key Trial Info
Start Date :
September 7 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 5 2021
Estimated Enrollment :
657 Patients enrolled
Trial Details
Trial ID
NCT04498273
Start Date
September 7 2020
End Date
August 5 2021
Last Update
February 17 2022
Active Locations (71)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Southern California
Los Angeles, California, United States, 90033
2
Stanford University School of Medicine
Palo Alto, California, United States, 94304
3
Zuckerberg San Francisco General
San Francisco, California, United States, 94143
4
Olive View-UCLA Medical Center
Sylmar, California, United States, 91342